- Intermediate
- Varenicline tartrate 230615-70-0
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
News Center
Aprepitant Intermediate 200000-59-5
【Catalogue Number】AP0602
【CAS #】200000-59-5
【Molecular formula】 C27H26F7NO5S
【Molecular Weight】609.55
Alias |
Aprepitant Intermediate |
Catalog Number |
AP0602 |
CAS # |
200000-59-5 |
Molecular Formula |
C27H26F7NO5S |
Molecular Weight |
609.55 |
Structural Formula |
|
Product Introduction CAS 200000-59-5 US-DMF No. 27597 |
(2R, 3S) -2-[(1R) -1- [3,5-bis (trifluoromethyl) phenyl] ethoxy] -3- (4-fluorophenyl) Morpholine p-toluenesulfonic acid salt -morpholine hydrochloride, American Chemical Abstracts Registry Number cas 200000-59-5. This product (cas 200000-59-5) is an intermediate of aprepitant. Aprepitant was the first neurokinin approved by the US FDA in 2003. (NK-1) receptor blocker, which blocks the action of substance P by binding to the NK-1 receptor (mainly present in the central nervous system and its periphery). This product can cross the blood-brain barrier and occupy the NK-1 receptor in the brain. It has selectivity and high affinity, and has a high affinity for NK. 2 and NK-3 receptor affinity is very low. At the same time, this product has a low affinity for the targets of other drugs (such as dopamine receptors, 5 HT receptors) for the treatment of chemotherapy-induced nausea and vomiting symptoms. |
VIWIT 沪ICP备12014533号-2